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RESEARCH Open Access
Mitogen activated protein kinase phosphatase-1
prevents the development of tactile sensitivity in
a rodent model of neuropathic pain
Christian Ndong1,4, Russell P. Landry1, Joyce A. DeLeo1,2,3 and Edgar Alfonso Romero-Sandoval1,2,5*
Abstract
Background: Neuropathic pain due to nerve injury is one of the most difficult types of pain to treat. Following
peripheral nerve injury, neuronal and glial plastic changes contribute to central sensitization and perpetuation of
mechanical hypersensitivity in rodents. The mitogen activated protein kinase (MAPK) family is pivotal in this spinal
cord plasticity. MAPK phosphatases (MKPs) limit inflammatory processes by dephosphorylating MAPKs. For
example, MKP-1 preferentially dephosphorylates p-p38. Since spinal p-p38 is pivotal for the development of
chronic hypersensitivity in rodent models of pain, and p-p38 inhibitors have shown clinical potential in acute and
chronic pain patients, we hypothesize that induction of spinal MKP-1 will prevent the development of peripheral
nerve-injury-induced hypersensitivity and p-p38 overexpression.
Results: We cloned rat spinal cord MKP-1 and optimize MKP-1 cDNA in vitro using transfections to BV-2 cells. We
observed that in vitro overexpression of MKP-1 blocked lipopolysaccharide-induced phosphorylation of p38 (and
other MAPKs) as well as release of pro-algesic effectors (i.e., cytokines, chemokines, nitric oxide). Using this cDNA
MKP-1 and a non-viral, in vivo nanoparticle transfection approach, we found that spinal cord overexpression of
MKP-1 prevented development of peripheral nerve-injury-induced tactile hypersensitivity and reduced pro-
inflammatory cytokines and chemokines and the phosphorylated form of p38.
Conclusions: Our results indicate that MKP-1, the natural regulator of p-p38, mediates resolution of the spinal
cord pro-inflammatory milieu induced by peripheral nerve injury, resulting in prevention of chronic mechanical
hypersensitivity. We propose that MKP-1 is a potential therapeutic target for pain treatment or prevention.
Keywords: Phosphatases, MKP-1, Spinal cord, p38, Kinases, Allodynia, Nanoparticle, Nanotechnology
Background
Chronic pain affects 116 million Americans and is esti-
mated to cost over $560–635 billion per year (including
health care and lost productivity) in the U.S. [1]. A large
population of chronic neuropathic pain patients does not
experience adequate relief with current treatments [2,3].
Therefore, identification of novel targets that allow the
development of novel, more efficacious drugs is
necessary.
Following peripheral insults such as nerve injury, sev-
eral changes take place in the spinal cord, including
glial responses and neuronal (central) sensitization. Both
phenomena are associated with chronic hypersensitivity.
Among the major pathways that determine the pro-
algesic/pro-inflammatory phenotype in spinal cord fol-
lowing peripheral nerve injury are the MAPK pathways.
Phosphorylation of MAPKs and the subsequent produc-
tion of pro-inflammatory effectors in spinal cord are in-
strumental in the genesis and maintenance of acute and
chronic pain [4]. The mechanisms by which peripheral
MAPK phosphorylation results in allodynia (nociceptive
response to innocuous stimuli) involve, at least in part,
the production of pro-algesic effectors that sensitize
spinal cord neurons and reinforce glial pro-inflamma-
tory phenotypes [5,6]. Additionally, MAPKs expressed
in neurons lead to increased neuronal excitability, con-
tributing to the acute phase and long-lasting central
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sensitization in pain conditions [5]. Therefore, periph-
eral nerve-injury-induced MAPK dysregulation is inte-
gral for the perpetuation of pain [4].
Among MAPKs, p38 has particular clinical relevance.
Drugs with novel mechanisms of action, such as inhib-
ition of p-p38 (phosphorylated p38), have shown poten-
tial to treat postoperative pain [7] and neuropathic pain
[8] in humans. Similarly, the deactivation of spinal p-p38
reverses peripheral nerve-injury-induced hypersensitivity
[9,10] and persistent postoperative pain in rats [11].
In the periphery, p38 phosphorylation is instrumental
in the development of inflammatory processes involving
the efficacious production of pro-inflammatory cytokines
[12], a mechanism also observed in spinal cord in pain
models [13]. These peripheral processes are limited
under normal conditions by natural regulators such as
MAPK phosphatase-1 (MKP-1), leading to resolution of
inflammation [12], a phenomenon that seems disrupted
in spinal cord in chronic pain conditions where MAPKs
are persistently phosphorylated.
Our laboratory has identified MKPs as potential anal-
gesic targets that may control spinal MAPK phosphoryl-
ation [14]. MKPs are the major regulators of MAPKs
and possess substrate specificity; thus, for example,
MKP-1 preferentially regulates p-38 and, to a lesser ex-
tent, c-Jun N-terminal kinase (JNK) [10]. Thus far, the
role of MKPs has not been elucidated in pain models.
We hypothesized that spinal induction of MKP-1 will
prevent peripheral nerve-injury-induced mechanical allo-
dynia in a rat model. First, and due to the low efficacy
for in vitro transfections using primary cells, we opti-
mized our genetic tools using an immortalized cell line.
We preferred to use a microglial cell line, BV-2 instead
of a non-central nervous system cell line since our hy-
pothesis is tested in vivo in the spinal cord. Second, once
our spinal cord MKP-1 cDNA was optimized in vitro, we
used a nanoparticle approach and in vivo spinal cord
transfections to induce MKP-1 and tested its effects on
downstream pro-algesic molecules.
Results
Spinal MKP-1 expression in naïve rats, and in rats
undergone sham or L5 nerve transection surgery
We sought to determine the expression level of MKP-1
in rats that underwent L5 nerve transection or L5
nerve-exposure sham surgery. Compared to the naïve
group, the sham group displayed an increase of spinal
MKP-1 protein at postoperative days 1 and 4. In con-
trast, spinal MKP-1 following L5 nerve transection did
not differ from the naïve group on postoperative days 1
or 4, and was significantly lower than spinal MKP-1 in
the sham group on postoperative day 4 (Figures 1a, 1b).
We hypothesize that peripheral nerve injury prevents an
increase in MKP-1, which allows p38 to be sustainably
phosphorylated [13]. Therefore, we tested whether restor-
ation of spinal MKP-1 in neuropathic pain conditions lim-
its p-p38 and the downstream production of pro-
inflammatory products and reduces tactile sensitivity.
In vitro overexpression of MKP-1 in microglial cells
We cloned the rat MKP-1 cDNA from rat spinal cord
homologous to the cloned MKP-1 (NM_053769) and
first tested its functional effects inducing stable overex-
pression in an immortalized mouse BV-2 microglial cell
line, as previous optimization to its use in in vivo
experiments. There were two reasons to use BV-2
microglial cells for this optimization process. First, the
transfection of primary cells is challenging, results in
cell death and its efficiency is poor (30-40%) with virtu-
ally no advances in new technologies in the last decade
[15,16]. Second, we consider more relevant the use of a
cell line that is derived from central nervous system
cells, microglia, instead of from peripheral origins
(HELA, CHO, etc.).
We observed an increase in MKP-1 mRNA and protein
in MKP-1 stably expressing cells (Figures 2a, 2b). These
results also confirm the specificity of our antibody used
for Western blot and immunofluorescence, since we
observed that this MKP-1 antibody detected higher levels
of MKP-1 protein in stably expressing MKP-1 BV-2
cells compared to normal BV-2 cells (Figure 2b).
Overexpressing MKP-1 BV-2 cells challenged with
Figure 1 MKP-1 expression in spinal cord following peripheral
nerve injury. Quantification of MKP-1 protein (a) and representative
Western blot of MKP-1 expression (b) in L5–L6 spinal cord of naïve
rats and of rats that have undergone sham (Sh) or L5 nerve
transection (L5NT or NT) surgery (n = 3–6) on postoperative days 1
(D1) and 4 (D4) . *P< 0.05 for sham versus naïve on postoperative
days 1 and 4, also between sham and L5 nerve transection groups
on postoperative day 4. All data are expressed as mean ± s.e.m.
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lipopolysaccharide (LPS, 1 μg/ml) expressed lower levels
of p-p38 (77 ± 4% and 77 ± 2% of control at 1 and 2 hr
respectively, two replicates, Figure 2b) and p-JNK (80 ±
3% and 82 ± 3% of control at 1 and 2 hr respectively, two
replicates, Figure 2b). Likewise, cells overexpressing
MKP-1 that were challenged with LPS produced less IL-6,
TNF-α, nitrite (nitric oxide metabolite) and monocyte
chemoattractant protein (MCP)-1 as compared to control
cells (normal, non-overexpressing MKP-1, LPS-treated
BV-2 cells, Figures 2d–g). We also confirmed that ~90% of
BV-2 cells were transfected with an Alexa-555 labeled
siRNA (Figure 3a) and that a siRNA against MKP-1
reduced the MKP-1 expression in a concentration-
dependent manner in BV-2 cells stably expressing MKP-1
(Figure 3b). This siRNA blocked the MKP-1-induced re-
duction of mRNA for IL-6 and IL-1β (Figures 3c, 3e) but
not of mRNA for TNF-α (Figure 3d); it blocked MKP-1-
induced reduction of MCP-1 and IL-6 (Figures 3f, 3g) but
not of TNF-α or NO (Figures 3h, 3i). These results show
the reliability of our MKP-1 cDNA since it demonstrates
functionality. Therefore, we decided to use this MKP-1
cDNA in an in vivo setting.
In vivo overexpression of MKP-1 in spinal cord of rats
undergone L5 nerve transection
We then sought to determine the feasibility of a non-
viral vector nanoparticle system, polyethylenimine (PEI),
for spinal cord tissue gene delivery [17]. PEI complexed
with GFP cDNA administered intrathecally to naïve rats
induced a cellular gene expression for two days (data not
shown), in agreement with previous observations [17].
PEI complexed with MKP-1 cDNA (N/P = 15) injected
i.t. in rats at the time of L5 nerve transection induced
spinal MKP-1 mRNA and protein expression 4 days
after surgery and treatment compared to the control
groups (PEI only and PEI + empty vector pcDNA3.1)
(Figures 4a–c). MKP-1 was expressed in Iba-1-expressing
microglia, NeuN-expressing neurons, and GFAP- or S100b-
expressing astrocytes (Figure 4d).
The rats over-expressing MKP-1 (PEI +MKP-1 cDNA)
did not develop mechanical allodynia for at least four days
following peripheral nerve injury when compared to base-
line and the PEI-only control rats (Figure 5a). In order to
directly test that these results were due to MKP-1 expres-
sion, we also include a group with PEI + empty vector
Figure 2 In vitro characterization of rat MKP-1 overexpression. MKP-1 mRNA levels (a, qRT-PCR) and Western blot of MKP-1 protein (b) in
normal BV-2 cells and stably MKP-1 overexpressing BV-2 cells. (c) Representative Western blots of p-p38, and p-JNK expression in BV-2 cells stably
overexpressing MKP-1 following 1 or 2 h incubation in medium (control alone) or lipopolysaccharide (LPS) stimulation (1 μg/ml). IL-6 (d), TNF-α
(e), nitrite (f), and MCP-1) (g) release in control (normal) and stably expressing MKP-1 BV-2 cells challenged with LPS (1 μg/ml) for 6 or 12 h.
Results are expressed as mean ± s.e.m. of three experiments in triplicate. *P< 0.05 vs. control BV-2 cells.
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pcDNA3.1, which did not prevent the development of per-
ipheral nerve-injury-induced hypersensitivity, in accord-
ance with the lack of spinal cord overexpression of MKP-1
mRNA or protein of this group.
Spinal MKP-1-overexpressing rats also displayed lower
levels of spinal p-p38 (Figures 5b, 5c), IL-1β, IL-6, TNF-α,
and MCP-1 as compared to the PEI-only or PEI + empty
vector groups (Figures 6 a–d). Phosphorylated p38 was
preferentially expressed in Iba-1-expressing microglia,
but not in S100b-expressing astrocytes or NeuN-expres-
sing neurons (Figure 5d), in agreement with previous
observations [13].
Discussion
We have shown that spinal cord over-expression of
MKP-1 reduces peripheral nerve-injury-induced spinal
Figure 3 Reversal effects of BV-2 cell MKP-1 induction in cytokine production by siRNA MKP-1 knockdown. (a) Efficient siRNA BV-2 cell
transfection using Alexa-555 red fluorescent-labeled siRNA. (b) MKP-1 mRNA level in BV-2 cells stably expressing MKP-1 after 24 h transfection with
MKP-1 siRNA compared to negative control siRNA and vehicle treated cells. IL-6 (c), TNF-α (d), and IL-1β (e) mRNA quantification (qRT-PCR) in
control (normal) and stably expressing MKP-1 BV-2 cells transfected 24 h with a negative siRNA, or a siRNA against MKP-1 and challenged with
LPS (1 μg/ml) for 6 h (IL-6 and TNF-α) or 12 h (IL-1β). Since MKP-1 siRNA at 10 nM displayed an opposite effect than expected in TNF-α mRNA
(potential non-specific effect), 1 nM was used for protein release experiments. Monocyte chemoattractant protein (MCP)-1 (f), IL-6 (g), TNF-α (h),
and nitrite (i) release in control (normal) and stably expressing MKP-1 BV-2 cells transfected 24 h with a negative siRNA, or a siRNA against MKP-1
and challenged with LPS (1 μg/ml) for 6 h (MCP-1, IL-6, and TNF-α) or 12 h (nitrite). Results are expressed as mean ± s.e.m. of three experiments in
duplicate. *P< 0.05 vs. BV-2 cells stably expressing MKP-1 (pMKP1 +).
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p-p38, presumably by dephosphorylation, which subse-
quently results in reduction of pro-inflammatory/pro-
algesic effectors, preventing development of chronic
allodynia.
Spinal cord MAPKs contribute to the perpetuation of
chronic pain. Dual-specificity phosphatases (i.e., MKPs)
dephosphorylate MAPKs, which reduces pro-inflamma-
tory factor production and eventually induces resolution
of inflammatory processes [18]. There are 16 identified
dual-specificity MKPs [18]. MKP-1 is an immediate early
gene product that preferentially dephosphorylates p-p38
over other MAPKs [18]. However, MKP-1 is also able to
regulate p-ERK or p-JNK in some cases [18].
The acute and persistent spinal phosphorylation of p38
is instrumental in the development and maintenance of
peripheral nerve-injury-induced allodynia [13]. In a
rodent model of acute postoperative pain, skin-incision-
induced p-p38 spontaneously returns to basal levels in
parallel with resolution of allodynia [19]. The role of p-p38
in the initiation of acute postoperative pain has been
demonstrated in this animal model of postoperative pain
[19] and in humans [7]. Similarly, we have previously
shown a functional association between persistent spinal
p-p38 and persistent postoperative allodynia in a rat paw
incision model [11]. Importantly, it has recently been
shown that a p-p38 inhibitor is effective in reducing
chronic pain in patients [8]. These data suggest that the
transition from acute to chronic pain may be explained by
an inability to restore basal MAPK phosphorylation of
p-p38 in the spinal cord. Our data argue for this assump-
tion. Spinal MKP-1 expression did not differ between per-
ipheral nerve injury and naïve groups. However, the sham
Figure 4 In vivo induction of spinal MKP-1. Quantification of MKP-1 mRNA (n = 3) (a) and of MKP-1 protein (n = 3) (b), as well as a
representative Western blot of MKP-1 expression (c), in L5–L6 spinal cord in rats that have undergone L5 nerve transection surgery and been
treated i.t. with PEI only, PEI + empty cDNA, and PEI + MKP-1 cDNA four days after treatment and surgery. *P< 0.05 versus PEI only or PEI + empty
vector. All data are expressed as mean ± s.e.m. (d) Representative images obtained by confocal microscopy and immunofluorescence depicting
MKP-1 (in green) and the microglial cell marker Iba-1 (in red), the neuronal marker NeuN (in red), and the astrocytic cell markers GFAP (in red)
and S100b (in red) in spinal cord of rats four days after L5 nerve transection and treated with PEI + MKP-1 cDNA or PEI only. Arrows indicate
co-regionalization (in yellow/orange). Arrowheads show punctate co-regionalization in NeuN-expressing neurons.
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group displayed a higher level of spinal MKP-1 than the
peripheral nerve injury group. These data suggest that skin
incision results in an increase of spinal MKP-1, possibly to
prevent p38 activation. In addition, peripheral nerve injury
may limit MKP-1 expression after surgery, which allows
p38 to be sustainably phosphorylated and contributes to
peripheral nerve injury-induced allodynia. The therapeutic
potential of p-p38 dephosphorylation by small molecules
in chronic pain patients [8] also argues for the clinical rele-
vance of our current findings and for the potential of
MKP-1 as a target for the development of novel drugs to
treat or prevent pain conditions.
Kinase phosphorylation requires adenosine triphos-
phate, while MKPs produce dephosphorylation by direct
enzymatic action on the substrate, namely p-p38. This
MKP mechanism of action is more efficient and may
confer an enzymatic potency of 100–1000-fold over kin-
ase activity [18]. This characteristic of MKPs makes them
an attractive drug target, since modest induction of MKP
expression may be a potent modulator of downstream
pro-inflammatory molecules (e.g., MAPKs) [18]. In fact,
the MKP-1 induction obtained with our approach was
relatively modest (~25%), but this seems sufficient to sig-
nificantly reduce p-p38 and cytokines in spinal cord and
so produce overt and clear antinociceptive effects in a rat
model of neuropathic pain. These findings are in accord-
ance with the relatively higher potency of MKP-1 over
the kinases that phosphorylate p38 [18]. This is relevant
because neuropathic pain is one of the most difficult
types of pain to treat in humans [2,3], and in general the
hypersensitivity behaviors observed in rodent models of
Figure 5 Effects of in vivo induction of spinal MKP-1 in
behavioral hypersensitivity and spinal p-p38 expression.
Withdrawal threshold to mechanical stimulation (a) in rats undergone
L5 nerve transection surgery and treated i.t. with PEI only (n = 9), PEI +
empty cDNA (n = 4), and PEI +MKP-1 cDNA (n = 9) four days after
treatment and surgery. Quantification of p-p38 protein (b) and
representative Western blot of p-p38 (c) expression from L5–L6 spinal
cord of rats that have undergone L5 nerve transection surgery and
been treated i.t. with PEI only (n= 3), PEI + empty cDNA (n= 3) and PEI +
MKP-1 cDNA (n= 3) four days after treatment and surgery. *P< 0.05
versus PEI only or PEI + empty vector. All data are expressed as
mean ± s.e.m. (d) Representative images obtained by confocal
microscopy and immunofluorescence depicting p-p38 (in green)
and the microglial marker Iba-1 (in red), the neuronal marker NeuN (in
red), and the astrocytic marker S100b (in red) in spinal cord of rats four
days after L5 nerve transection and treated with PEI + MKP-1 cDNA or
PEI only. Arrows indicate co-regionalization (in yellow/orange).
Figure 6 Effects of in vivo induction of spinal MKP-1 in
pro-inflammatory/algesic effectors. Concentrations of IL-1β (a), IL-6
(b), TNF-α (c), and MCP-1 (d) from L5–L6 spinal cord of rats
undergone L5 nerve transection surgery and treated i.t. with PEI only
(n = 5), PEI + empty cDNA (n = 4), and PEI + MKP-1 cDNA (n = 9) four
days after treatment and surgery. *P< 0.05 versus PEI only or PEI +
empty vector. All data are expressed as mean ± s.e.m.
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chronic pain [20] are more difficult to reverse than those
displayed in rodent models of acute pain [21].
Phosphorylated p38 governs, at least in part, the produc-
tion of microglial pro-inflammatory factors [9,10] believed
to enhance activation of sensory neurons and sensitize the
nociceptive system [22], contributing to rat-model beha-
viors suggestive of human pain [4,23]. Microglia, under in-
flammatory conditions, acquire an anti-inflammatory
phenotype following MKP overexpression, manifested by a
reduction of MAPK phosphorylation and downstream pro-
inflammatory mediators such as cytokines or chemokines
[10,14]. Therefore the effects of spinal MKP-1 induction in
our current study may be a result of action in microglia.
MKP-1 can produce similar anti-inflammatory effects in
astrocytes and neurons; in fact, we did observe MKP-1 ex-
pression in these types of cells. However, downstream
modulation of p-p38 by MKP-1 (p-p38 is the main sub-
strate of MKP-1) was observed preferentially in microglial
cells (Iba-1 expressing cells), in agreement with previous
observations [13]. This finding argues for the potential
relevance of microglial cell functions in the molecular and
antinociceptive effects observed in this study.
We have previously shown in vitro that MKP-1 induc-
tion by a cannabinoid receptor type 2 agonist (JWH015)
in primary microglial cells resulted in dephosphorylation
of MAPKs and reduction of TNF-α production [14].
Others have shown similar findings with the endocanna-
binoid anandamide [24]. In that study, anandamide-
induced MKP-1 reduced microglial NO release and was
neuroprotective in a model of central inflammation.
Similarly, others have shown that the induction of MKP-
1 by dexamethasone induced p-38 dephosphorylation
and a reduction of MCP-1 in rat primary microglia [10].
Spinal pro-inflammatory factors, such as TNF-α or
MCP-1, contribute to generation of central sensitization
and maintenance of chronic hypersensitivity [25-27].
Some of these pro-inflammatory factors, such as TNF-α,
may cause direct nerve sensitization [28] and promote
phosphorylation of spinal microglial p38, contributing to
behavioral hypersensitivity in rodent models of neuro-
pathic pain [9,29,30]. This reverberant pro-algesic loop
between cytokines and MAPKs seems to be disrupted by
the induction of MKP-1 in our study, which ultimately
results in reduction of behavioral hypersensitivity
induced by peripheral nerve injury. These earlier data,
together with our current results, support the interpret-
ation that MKP-1 is an important player in the mechan-
isms underlying chronic pain.
Since cytokines that are downstream p-p38 can also in-
duce p38 phosphorylation [9,29,30], an alternative
interpretation of our data may be that overexpressed
MKP-1 directly reduces cytokine expression, and this may
result in a reduction of p-p38. This possibility seems un-
likely since MKP-1 is a enzyme with defined and identified
substrates and actions: MAPKs and dephosphorylation re-
spectively [18]. There is no literature description of phos-
phatases with direct effects on cytokines, which do not
require phosphorylation to be active. Additionally, it is
well established that cytokine production depends in part,
and is downstream MAPK signaling pathways [9,10].
However, we recognize that the observed effects on cyto-
kine production due to p38 dephosphorylation induced by
MKP-1 overexpression may contribute to the overall re-
duction of p-p38 as a downstream mechanism.
In vivo spinal MKP-1 induction did not change spinal
p-JNK expression (data not shown), but we did observe
an increase in the phosphorylated form of extracellular
signal-regulated protein kinase (ERK)-1/2 (data not
shown). This is in agreement with the preference of
MKP-1 to dephosphorylate p-p38 rather than p-ERK-1/2
[18]. Even though p-ERK signaling has been associated
with allodynia, p-ERK is necessary for the MKP-1 struc-
tural stabilization, which prevents MKP-1’s early break-
down and enhances its activity [31,32]. Our data show
the potentially greater relevance of spinal p-p38, compared
to p-ERK, in the generation of peripheral nerve-injury-
induced tactile allodynia.
In summary, our current results show that the spinal
cord induction of MKP-1 is sufficient to prevent the
development of peripheral nerve injury-induced allody-
nia for at least four days. Our study warrants further
studies to determine whether these behavioral effects
are only affecting the mechanisms governing the devel-
opment of chronic allodynia or are also blocking the
mechanisms of chronic hypersensitivity. Likewise, our
study warrants further investigation on the potential
role of other phosphatases in pain states, and the po-
tential role of MKP-1 in other types of pain, such as
acute pain.
Conclusions
In conclusion, we have uncovered that the immunomodula-
tory molecule MKP-1, which is involved in the resolution of
inflammatory processes in the periphery, is also able to re-
solve the spinal pro-inflammatory phenotype induced by
peripheral nerve injury. We demonstrated that MKP-1
retains its substrate specificity, namely p-p38, in spinal
cord (as also observed in other systems) and that depho-
sphorylation of p-p38 may explain the reduction of spinal
pro-algesic factors (cytokines and chemokines) and mech-
anical hypersensitivity in a rat model of neuropathic pain.
We identified MKP-1 as a potential new target for drug
development. The clinical utility of MKP-1 inducers is
supported by the greater potency of MKPs over kinase ac-
tivity, which will theoretically possess analgesic efficacy
with modest molecular effects as compared to current
p-p38 inhibitors. The clinical potential of p-p38 modu-
lators has already been shown; our findings may provide
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the foundation for the development of novel drugs with
more specific MKP-1 induction than cannabinoids or
glucocorticoids.
Methods
Cloning of the rat MKP1 gene
Spinal cord tissue from Sprague Dawley rats (Harlan,
Indianapolis, IN, 250 g) was harvested and stored at –
80°C. Frozen tissues were homogenized and total RNA was
extracted using RNA easy columns (Qiagen, Basel, Switzer-
land), following the manufacturer’s protocol. Total RNA
was stored at –20°C until further use. Single strand cDNA
was synthesized from 1 μg of rat spinal cord total RNA
using the Quantitect reverse transcription kit (Qiagen,
Basel, Switzerland), following the manufacturer’s protocol.
For MKP-1 polymerase chain reaction (PCR), forward
(5’CGACAGACTATTTCTGGAGAGCTGC3’) and reverse
(5’CGGTGGCACGTGAAACTCCACA3’) primers were
designed to be homologous to the rat dual-specificity phos-
phatase 1 gene (Genbank accession number NM_053769).
These primers were used to generate 1.198 kb PCR frag-
ment from spinal cord cDNA samples. PCR was performed
as follows: 95°C for 5 min followed by 30 cycles at 95°C for
15 sec, 61°C for 1 min, 72°C for 1 min 15 sec, and 72°C
for 10 min. The PCR product was gel-purified and
cloned into pcDNA3.1 expression vector (Invitrogen, San
Diego, CA). The MKP-1 gene was sequenced on both
strands using the Big Dye terminator v3.1 cycle sequencing
kit (Applied Biosystems, Foster city, CA) and confirmed
the expected rat MKP-1.
Cell culture, transfection, and lipopolysaccharide (LPS)
treatment
The immortalized mouse microglial cell line BV-2 (a
generous gift of Dr. Weihua Zhao, Methodist Hospital,
Houston, TX) was cultured in DMEM (Mediatech,
Manassas, VA) supplemented with 10% charcoal-
stripped FBS (Hyclone), 1.1% GlutaMax (Invitrogen, San
Diego, CA), and 1% Penicillin-Streptomycin (100 U/ml
penicillin, 100 μg/ml streptomycin, Mediatech) and
maintained in 5% CO2 at 37°C. BV-2 cell viability was
assessed by trypan blue staining (Sigma, St. Louis, MO)
and hemocytometer. A cell line stably expressing MKP-
1 was created by transfection of rat MKP-1 (5 μg)
cDNA into 1x106 BV-2 by electroporation (Lonza Biolo-
gics, Basel, Switzerland) following manufacturer’s
instructions. After 48 h, cells were selected in growth
medium containing neomycin (G418 sulfate, 800 μg/ml)
for about 2 weeks. Stable transformants were then split
at different dilutions in plates containing growth
medium and neomycin selection drug. Cells were chal-
lenged with 1 μg/mL of LPS (0111:B4 serotype, Sigma,
St. Louis, MO) in complete media for 1, 2, 6, and 12 h.
Following LPS treatment, supernatants were removed
and stored at –80oC until nitric oxide (NO) and cyto-
kine measurement. Cells were used for quantitative RT-
PCR and Western blot analyses.
The stealth siRNA oligonucleotides were synthesized
by Invitrogen (Invitrogen, San Diego, CA) with sequence
complementary to rat MKP-1 5’UCGUGAAGCAGA
GGCGGAGUAUUAU3’ and 5’AUAAUACUCCGCCUCU
GCUUCACGA3’. The stealth siRNA negative control
duplex was used as control oligonucleotide (5’UUCCUC
UCCACGCGCAGUACAUUUA3’ and 5’UAAAUGUAC
UGCGCGUGGAGAGGAA3’). Transfection efficiency
(~85%) was monitored using BLOCK-iT Alexa Fluor red
fluorescent oligo (Invitrogen, San Diego, CA). Stealth
MKP-1 siRNAs (0.1, 1, and 10 nM) were transfected for
24 hr in BV-2 stably expressing MKP-1 using RNAi max
transfection reagent (Invitrogen, San Diego, CA), follow-
ing manufacturer’s instructions.
Quantitative real time (RT)-PCR
For mRNA quantification, total RNA isolated from BV-2
was reverse transcribed into single-strand cDNA as
described above. Quantitative RT-PCR was performed using
a 96-well plate with the Applied Biosystems 7500 Real-Time
PCR system (Applied Biosystems, Foster city, CA) accord-
ing to the following conditions: 1 cycle of 50°C for 2 min, 1
cycle of 95°C for 10 min, then 40 cycles at 95°C for 15 sec,
60°C for 1 min. All samples were run in duplicate using
Taqman gene expression assays (Applied Biosystems, Foster
City, CA) with rat MKP-1 (Rn00678341_g1) predesigned
and preformulated primer and probe. Expression of MKP-1
was normalized to a predesigned and preformulated rat
(Rn01775763_g1) or mouse (Mm99999915_g1) control
gene GAPDH (Applied Biosystems, Foster City, CA). The
difference in MKP-1 mRNA expression between treatments
was analyzed using the comparative CT method. The
threshold cycle (CT) is defined as the cycle at which the
amount of amplified PCR product from the target
cDNA reaches a fixed threshold. In each treatment,
ΔCT =MKP1CT – CT for the endogenous reference,
GADPH. ΔΔCT = ΔCT treatment – ΔCT control. The N-fold
of differential expression of MKP-1 transcript in the
treated group compared to that in the control group is
expressed as 2- ΔΔCT. This number is converted to per-
cent of control, where control is set at 100. Total RNA
for each sample was also included during each run as a
negative control. Predesigned and preformulated primers
and probes for rat and mouse cytokines interleukin (IL)-6,
tumor necrosis factor (TNF)-α, and IL-1β mRNAs—i.e.,
for rat, Rn 99999011_m1, Rn 99999017_m1, and Rn
00580432_m1 respectively, and for mouse, Mm
99999064_m1, Mm 00443258_m1 and Mm 01336189_m1
respectively—were used for quantitative RT-PCR as
described above.
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Western blot analyses
BV-2 cell protein or hemi-sectioned spinal cord (ipsilat-
eral to injury) was collected in 100 μL of 1x Laemmli
buffer (Bio-Rad, Hercules, CA) containing either 5% 2-β
Mercaptoethanol (Sigma, St. Louis, MO). Protein (40–
50 μg) or standard protein markers were subjected to
SDS polyacrylamide gel electrophoresis (10% or 18% gels,
Bio-Rad, Hercules, CA) and transferred to polyvinylidene
difluoride (PVDF, Bio-Rad, Hercules, CA) membranes.
Membranes were blocked with 5% BSA in TBS-Tween
20 (0.05%, Sigma, St. Louis, MO), then incubated over-
night at 4°C with mouse anti rat MKP-1 monoclonal
antibody (1:500, Santa Cruz Biotechnology, Santa Cruz,
CA), mouse anti-phospho-ERK 44/42 (Phospho-MAP
Kinase 1:500, Cell Signaling, Danvers, MA), mouse anti-
phospho-p38 (1:500, Cell Signaling, Danvers, MA), or
mouse anti-phospho-JNK (1:500, Cell Signaling, Danvers,
MA). Blots were incubated with goat HRP-conjugated
secondary antibody (1:3000, Pierce, Rockford, IL), treated
with SuperSignal West Femto Maximum Sensitivity Sub-
strate (Thermo Fisher Scientific, Rockford, IL), and
imaged with Syngene G-box (Synoptics, Frederick, MD).
Membranes were stripped and re-probed with rabbit
anti-ERK 44/42 (Total MAP Kinase 1:500, Cell Signaling,
Danvers, MA), rabbit anti-p38 (total MAP kinase 1:500,
Cell Signaling, Danvers, MA), rabbit anti-JNK (1:500,
Cell Signaling, Danvers, MA), or mouse anti-β-actin
antibody (1:3000, Abcam, Cambridge, MA). Band density
was quantified in relation to loading controls using Syn-
gene Tools software (Synoptics, Frederick, MD). MAPKs
were evaluated at 1 and 2 hr following LPS stimulation
in BV-2 cells, since these early activated molecules are
upstream cytokines, chemokines and nitric oxide pro-
duction (which were measured at later time points, 6
and 12 hr after LPS stimulation in BV-2 cells).
Griess assay (Nitric oxide production) and ELISA assays
Supernatants collected from LPS-treated cells or total
proteins (20 μg) extracted from L5 spinal cord were
assayed for (1) nitric oxide (NO), measured as nitrite,
using the Griess Assay (Promega, Madison, WI), (2)
MCP-1 using the BD OptEIA™ ELISA kits for mouse and
rat MCP-1 (BD Biosciences, San Diego, CA), and (3) IL-
1β, IL-6, and TNF-α using the respective R&D Systems
DuoSet ELISA (R&D Systems, Minneapolis, MN) kits
following the manufacturer’s protocol.
Animals, vector delivery, surgeries, and behavior testing
to assess allodynia
Sprague-Dawley rats weighing 250–300 g (Harlan) at the
start of the study were housed individually and main-
tained in 12:12 h light-dark cycle with ad libitum access
to food and water. All procedures were approved by the
Institutional Animal Care and Use Committee at
Dartmouth College (Dartmouth Medical School, Han-
over, New Hampshire) and in accordance with the Guide-
lines for Animal Experimentation of the International
Association for the study of Pain. Plasmid DNA expres-
sing MKP-1 (pcDNA-MKP-1) or empty plasmid DNA
(pcDNA3.1) used in this study was purified using an
endotoxin-free Qiagen plasmid purification kit and resus-
pended in sterile water. After determining the concentra-
tion of pcDNA-MKP-1 using 260 nm adsorption,
aliquots of 8 μg were stored at –20°C. The purity of
pcDNA-MKP-1 was determined by 260:280 nm adsorp-
tion and ranged between 1.9 to 2.0.
We used the in vivo non-viral nanoparticle preparation
polyethylenimine (PEI), in vivo-JetPEI (PEI, Polyplus
Transfection, New York, NY) for our in vivo gene trans-
fection and induction. Endotoxin-free PEI is a cationic
polymer that protects nucleic acids from degradation
when administered in vivo [33,34]. The positively
charged PEI-nucleic acid complex interacts with the cel-
lular membrane anionic proteoglycans, facilitating entry
of the molecule into cells by endocytosis [35]. Genes
complexed with PEI have shown efficient induction into
the brain and spinal cord parenchyma (glial and neur-
onal) of mice and rats when administered intrathecally
or intracerebrally [36-39]. This CNS tissue penetration is
not achieved with microparticles limited to the menin-
geal tissue following intrathecal administration [40].
CNS administration of PEI nanoparticles with DNA plas-
mids has shown minimal toxicity, no necrosis [36], no
inflammatory response [41], and no overt side effects in
CNS animal transfections [42]. Additionally, PEI trans-
fection does not alter the electrophysiological properties
of neurons [43], which makes this nanoparticle transfec-
tion agent a suitable tool for pain research.
On the day of intrathecal (i.t.) injection, aliquot of
pcDNA-MKP-1 or empty pcDNA3.1 was thawed on ice
and complexed with in vivo-JetPEI as described by the
manufacturer: 8 μg of pcDNA plus in vivo-JetPEI in 5%
glucose in a final ratio of nitrogen residues of in vivo-Jet-
PEI per nucleic acid phosphate of 15 (N/P = 15) and a
total volume of 20 ul. The preparation was incubated at
room temperature for 15 min before the injections. The
ready complex PEI + pcDNA-MKP1 (PEI +MKP-1, n = 9
animals), PEI + pcDNA alone (empty cDNA, n = 4 ani-
mals), or PEI alone (n = 9 animals) was administered by
lumbar-puncture i.t. injection using a Hamilton syringe
and a 25-gauge 5/8 hypodermic needle, as we have
described before [20], under brief inhalational anesthesia
(2–3% isoflurane in oxygen). The needle was inserted
intrathecally, on the midline between the fourth and fifth
lumbar vertebrae. Injection site was confirmed by stimu-
lation of nerves in the cauda equina when the needle
penetrated the dura and manifested with a brief and ob-
vious movement of the tail and/or the hind paws. The
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animals regained consciousness 2–3 min after discon-
tinuation of anesthesia.
Animals underwent L5 nerve transection (L5NT) pro-
cedure as previously described [20]. Briefly, rats were
anesthetized with 2% isoflurane in oxygen and a small
incision was made to the skin overlying L5–S1, followed
by retraction of the paravertebral musculature. The L6
transverse process was then removed and the L5 spinal
nerve identified, lifted slightly, and transected. The
wound was sutured. Sham surgeries were performed
similarly, except for nerve manipulation or transection.
Intrathecal injection of PEI + cDNAs or PEI only was
performed immediately after surgery.
Behavioral testing was performed to assess the devel-
opment of mechanical allodynia before injection or sur-
gery and on postoperative days 1–4 [20]. The withdrawal
threshold to mechanical stimuli was assessed ipsilaterally
to surgery using calibrated von Frey filaments (Stoelting,
Wood Dale, IL) and an up-down statistical method [44].
The investigator was blinded to treatment in all behav-
ioral tests.
Immunohistochemistry
Rats were deeply anesthetized with 2–3% isoflurane in
oxygen and transcardially perfused with 10 mM phos-
phate buffer saline (200 mL) followed by 4% formalde-
hyde (400 mL) at room temperature. The L5 portion of
the spinal cord was removed and placed in 30% sucrose
for 48–72 h at 4°C. The tissue was then frozen at –80°C
in optimal cutting temperature compound (Sakura Fine-
tek, Torrance, CA). Immunohistochemistry was per-
formed on transverse 20 μm L5 spinal cord free-floating
sections. The sections were blocked for 1 h in 5% normal
goat serum (NGS, Vector Labs, Burlingame, CA) and
0.01 Triton X-100 (Sigma) in PBS. Then the sections
were incubated overnight in mouse anti rat monoclonal
antibody for MKP-1 (1:100, Cell Signaling, Danvers,
MA). The next day, a TSA Signal Amplification Kit (Per-
kinElmer LifeSciences Inc, Boston, MA) was used, fol-
lowing the manufacturer’s instructions, to enhance the
visualization of MKP-1 expression. Sections were washed
2 times for 5 min in PBS then incubated in a biotinylated
Goat anti-rabbit secondary antibody for 1 h at 4°C. Sec-
tions were then washed, incubated in SA-HRP (1:100)
for 1 h at 4°C, washed again and incubated in the TSA
fluorophore (1:250) for 10 min at 4°C. Sections were
then washed again and incubated overnight in rabbit anti
rat antibody for ionized calcium binding adaptor mol-
ecule 1 (Iba-1, 1:1000, microglia marker, Wako, Rich-
mond, VA), rabbit anti glial fibrillary acidic protein
(GFAP, 1:10,000, astrocyte marker, Dako, Carpinteria,
CA), rabbit anti S100 calcium binding protein B (S100B,
1:15,000, astrocyte marker, Fitzgerald, Concord, MA), or
rabbit NeuN/Fox3 (NeuN, 1:10,000, neuron nuclear
marker, Biosensis, Australia). The next day sections were
washed three times, then incubated for 1 h in goat anti-
mouse Alexa 488 IgG3 and goat anti-rabbit Alexa 555
IgG secondary antibodies (1:250, Invitrogen). Tissue sec-
tions were washed, mounted on glass slides, dehydrated,
treated with Vectashield (Vector Labs, Burlingame, CA),
and sealed with a coverslip and nail polish. The specifi-
city of each antibody was tested by omitting the primary
antibody on 1–3 additional sections. All MAPK and cell
marker antibodies are widely used for their specificity.
We confirmed the specificity of our MKP-1 antibody by
using Western blots in MKP-1 overexpressing BV-2 cells
and normal BV-2 cells (see Results section). The follow-
ing groups were included to test MKP-1 antibody signal
amplification using the TSA kit: (1) only the anti-MKP-1
primary antibody (1:100) and the Alexa 555 Goat anti-
rabbit secondary antibody, (2) only the anti-MKP-1 pri-
mary antibody and the TSA kit, and (3) the TSA kit, the
cell marker primary, and the Alexa 555 Goat anti-rabbit
secondary antibody, but excluding the anti-MKP-1 pri-
mary antibody. All controls confirmed the specificity of
the complete co-stain. Sections for single antibody im-
munofluorescence were imaged with a Q-Fired cooled
CCD camera attached to an Olympus microscope. Con-
focal microscopy of dual antibody immunofluorescence
was performed with a Zeiss LSM 510 Meta confocal
microscope (Englert Cell Analysis Laboratory of Dart-
mouth Medical School), and images were prepared with
the Zeiss LSM software (Thornwood, NY) and Adobe
Photoshop software (San Jose, CA). All images were
taken from laminae I–II of dorsal horn spinal cord ipsi-
lateral to nerve injury.
Statistical analysis
All in vitro experiments were completed at least three
time. Data are expressed as mean ± s.e.m. Statistical ana-
lyses were completed using GraphPad Prism 5 (Graph-
Pad Software, Inc., San Diego, CA). One- or two-way
ANOVA and Bonferroni post test were used when
appropriate. Unpaired t-test was use for MKP-1 mRNA
expression and cytokine release. Significance was deter-
mined at a level of P< 0.05 or with exact p value where
available.
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